Jason J. Luke, MD, FACP, will be the Interim Associate Director for Clinical Research at UPMC Hillman Cancer Center beginning February 1, 2023. Dr. Luke is currently Director of Hillman’s Immunotherapy and Drug Development Center and a member of the Skin/Sarcoma Center. He is a multi-principal investigator (PI) of the Pittsburgh Cancer Consortium for the National Cancer Institute (NCI) Experimental Therapeutics Clinical Trials Network, clinical co-Leader for Project 3 of UPMC Hillman’s Melanoma and Skin Cancer SPORE, co-PI of the NCI-funded R01 grant “Immune Exclusion in Cancer Immunotherapy,” and a member of the NCI’s Investigational Drug Steering Committee.
Dr. Luke recently reported practice changing results of the KEYNOTE-716 trial, which established the role for and led to the FDA/EMA approval of anti-PD1 immunotherapy in stage II melanoma (Luke et al., Lancet 2022). Dr. Luke is actively involved in several professional societies including SITC (where he sits on the Board of Directors), AACR, ASCO, and the Society for Melanoma Research, having served on the scientific program committees for each.
As Interim Associate Director, Dr. Luke will be charged with reviewing and enhancing clinical research organization, support, and disease center functions in conjunction with Tess Cummings, RN, UPMC Hillman Cancer Center’s Vice President for Clinical Research Operations.
